Cargando…

Expert-based medication reviews to reduce polypharmacy in older patients in primary care: a northern-Italian cluster-randomised controlled trial

BACKGROUND: Evidence regarding clinically relevant effects of interventions aiming at reducing polypharmacy is weak, especially for the primary care setting. This study was initiated with the objective to achieve clinical benefits for older patients (aged 75+) by means of evidence-based reduction of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahlknecht, Angelika, Wiedermann, Christian J., Sandri, Marco, Engl, Adolf, Valentini, Martina, Vögele, Anna, Schmid, Sara, Deflorian, Felix, Montalbano, Carmelo, Koper, Dara, Bellmann, Romuald, Sönnichsen, Andreas, Piccoliori, Giuliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609829/
https://www.ncbi.nlm.nih.gov/pubmed/34814835
http://dx.doi.org/10.1186/s12877-021-02612-0
_version_ 1784602990629355520
author Mahlknecht, Angelika
Wiedermann, Christian J.
Sandri, Marco
Engl, Adolf
Valentini, Martina
Vögele, Anna
Schmid, Sara
Deflorian, Felix
Montalbano, Carmelo
Koper, Dara
Bellmann, Romuald
Sönnichsen, Andreas
Piccoliori, Giuliano
author_facet Mahlknecht, Angelika
Wiedermann, Christian J.
Sandri, Marco
Engl, Adolf
Valentini, Martina
Vögele, Anna
Schmid, Sara
Deflorian, Felix
Montalbano, Carmelo
Koper, Dara
Bellmann, Romuald
Sönnichsen, Andreas
Piccoliori, Giuliano
author_sort Mahlknecht, Angelika
collection PubMed
description BACKGROUND: Evidence regarding clinically relevant effects of interventions aiming at reducing polypharmacy is weak, especially for the primary care setting. This study was initiated with the objective to achieve clinical benefits for older patients (aged 75+) by means of evidence-based reduction of polypharmacy (defined as ≥8 prescribed drugs) and inappropriate prescribing in general practice. METHODS: The cluster-randomised controlled trial involved general practitioners and patients in a northern-Italian region. The intervention consisted of a review of patient’s medication regimens by three experts who gave specific recommendations for drug discontinuation. Main outcome measures were non-elective hospital admissions or death within 24 months (composite primary endpoint). Secondary outcomes were drug numbers, hospital admissions, mortality, falls, fractures, quality of life, affective status, cognitive function. RESULTS: Twenty-two GPs/307 patients participated in the intervention group, 21 GPs/272 patients in the control group. One hundred twenty-five patients (40.7%) experienced the primary outcome in the intervention group, 87 patients (32.0%) in the control group. The adjusted rates of occurrence of the primary outcome did not differ significantly between the study groups (intention-to-treat analysis: adjusted odds ratio 1.46, 95%CI 0.99–2.18, p = 0.06; per-protocol analysis: adjusted OR 1.33, 95%CI 0.87–2.04, p = 0.2). Hospitalisations as single endpoint occurred more frequently in the intervention group according to the unadjusted analysis (OR 1.61, 95%CI 1.03–2.51, p = 0.04) but not in the adjusted analysis (OR 1.39, 95%CI 0.95–2.03, p = 0.09). Falls occurred less frequently in the intervention group (adjusted OR 0.55, 95%CI 0.31–0.98; p = 0.04). No significant differences were found regarding the other outcomes. Definitive discontinuation was obtained for 67 (16.0%) of 419 drugs rated as inappropriate. About 6% of the prescribed drugs were PIMs. CONCLUSIONS: No conclusive effects were found regarding mortality and non-elective hospitalisations as composite respectively single endpoints. Falls were significantly reduced in the intervention group, although definitive discontinuation was achieved for only one out of six inappropriate drugs. These results indicate that (1) even a modest reduction of inappropriate medications may entail positive clinical effects, and that (2) focusing on evidence-based new drug prescriptions and prevention of polypharmacy may be more effective than deprescribing. TRIAL REGISTRATION: Current Controlled Trials (ID ISRCTN: 38449870), date: 11/09/2013. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-021-02612-0.
format Online
Article
Text
id pubmed-8609829
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86098292021-11-29 Expert-based medication reviews to reduce polypharmacy in older patients in primary care: a northern-Italian cluster-randomised controlled trial Mahlknecht, Angelika Wiedermann, Christian J. Sandri, Marco Engl, Adolf Valentini, Martina Vögele, Anna Schmid, Sara Deflorian, Felix Montalbano, Carmelo Koper, Dara Bellmann, Romuald Sönnichsen, Andreas Piccoliori, Giuliano BMC Geriatr Research BACKGROUND: Evidence regarding clinically relevant effects of interventions aiming at reducing polypharmacy is weak, especially for the primary care setting. This study was initiated with the objective to achieve clinical benefits for older patients (aged 75+) by means of evidence-based reduction of polypharmacy (defined as ≥8 prescribed drugs) and inappropriate prescribing in general practice. METHODS: The cluster-randomised controlled trial involved general practitioners and patients in a northern-Italian region. The intervention consisted of a review of patient’s medication regimens by three experts who gave specific recommendations for drug discontinuation. Main outcome measures were non-elective hospital admissions or death within 24 months (composite primary endpoint). Secondary outcomes were drug numbers, hospital admissions, mortality, falls, fractures, quality of life, affective status, cognitive function. RESULTS: Twenty-two GPs/307 patients participated in the intervention group, 21 GPs/272 patients in the control group. One hundred twenty-five patients (40.7%) experienced the primary outcome in the intervention group, 87 patients (32.0%) in the control group. The adjusted rates of occurrence of the primary outcome did not differ significantly between the study groups (intention-to-treat analysis: adjusted odds ratio 1.46, 95%CI 0.99–2.18, p = 0.06; per-protocol analysis: adjusted OR 1.33, 95%CI 0.87–2.04, p = 0.2). Hospitalisations as single endpoint occurred more frequently in the intervention group according to the unadjusted analysis (OR 1.61, 95%CI 1.03–2.51, p = 0.04) but not in the adjusted analysis (OR 1.39, 95%CI 0.95–2.03, p = 0.09). Falls occurred less frequently in the intervention group (adjusted OR 0.55, 95%CI 0.31–0.98; p = 0.04). No significant differences were found regarding the other outcomes. Definitive discontinuation was obtained for 67 (16.0%) of 419 drugs rated as inappropriate. About 6% of the prescribed drugs were PIMs. CONCLUSIONS: No conclusive effects were found regarding mortality and non-elective hospitalisations as composite respectively single endpoints. Falls were significantly reduced in the intervention group, although definitive discontinuation was achieved for only one out of six inappropriate drugs. These results indicate that (1) even a modest reduction of inappropriate medications may entail positive clinical effects, and that (2) focusing on evidence-based new drug prescriptions and prevention of polypharmacy may be more effective than deprescribing. TRIAL REGISTRATION: Current Controlled Trials (ID ISRCTN: 38449870), date: 11/09/2013. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-021-02612-0. BioMed Central 2021-11-23 /pmc/articles/PMC8609829/ /pubmed/34814835 http://dx.doi.org/10.1186/s12877-021-02612-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Mahlknecht, Angelika
Wiedermann, Christian J.
Sandri, Marco
Engl, Adolf
Valentini, Martina
Vögele, Anna
Schmid, Sara
Deflorian, Felix
Montalbano, Carmelo
Koper, Dara
Bellmann, Romuald
Sönnichsen, Andreas
Piccoliori, Giuliano
Expert-based medication reviews to reduce polypharmacy in older patients in primary care: a northern-Italian cluster-randomised controlled trial
title Expert-based medication reviews to reduce polypharmacy in older patients in primary care: a northern-Italian cluster-randomised controlled trial
title_full Expert-based medication reviews to reduce polypharmacy in older patients in primary care: a northern-Italian cluster-randomised controlled trial
title_fullStr Expert-based medication reviews to reduce polypharmacy in older patients in primary care: a northern-Italian cluster-randomised controlled trial
title_full_unstemmed Expert-based medication reviews to reduce polypharmacy in older patients in primary care: a northern-Italian cluster-randomised controlled trial
title_short Expert-based medication reviews to reduce polypharmacy in older patients in primary care: a northern-Italian cluster-randomised controlled trial
title_sort expert-based medication reviews to reduce polypharmacy in older patients in primary care: a northern-italian cluster-randomised controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609829/
https://www.ncbi.nlm.nih.gov/pubmed/34814835
http://dx.doi.org/10.1186/s12877-021-02612-0
work_keys_str_mv AT mahlknechtangelika expertbasedmedicationreviewstoreducepolypharmacyinolderpatientsinprimarycareanorthernitalianclusterrandomisedcontrolledtrial
AT wiedermannchristianj expertbasedmedicationreviewstoreducepolypharmacyinolderpatientsinprimarycareanorthernitalianclusterrandomisedcontrolledtrial
AT sandrimarco expertbasedmedicationreviewstoreducepolypharmacyinolderpatientsinprimarycareanorthernitalianclusterrandomisedcontrolledtrial
AT engladolf expertbasedmedicationreviewstoreducepolypharmacyinolderpatientsinprimarycareanorthernitalianclusterrandomisedcontrolledtrial
AT valentinimartina expertbasedmedicationreviewstoreducepolypharmacyinolderpatientsinprimarycareanorthernitalianclusterrandomisedcontrolledtrial
AT vogeleanna expertbasedmedicationreviewstoreducepolypharmacyinolderpatientsinprimarycareanorthernitalianclusterrandomisedcontrolledtrial
AT schmidsara expertbasedmedicationreviewstoreducepolypharmacyinolderpatientsinprimarycareanorthernitalianclusterrandomisedcontrolledtrial
AT deflorianfelix expertbasedmedicationreviewstoreducepolypharmacyinolderpatientsinprimarycareanorthernitalianclusterrandomisedcontrolledtrial
AT montalbanocarmelo expertbasedmedicationreviewstoreducepolypharmacyinolderpatientsinprimarycareanorthernitalianclusterrandomisedcontrolledtrial
AT koperdara expertbasedmedicationreviewstoreducepolypharmacyinolderpatientsinprimarycareanorthernitalianclusterrandomisedcontrolledtrial
AT bellmannromuald expertbasedmedicationreviewstoreducepolypharmacyinolderpatientsinprimarycareanorthernitalianclusterrandomisedcontrolledtrial
AT sonnichsenandreas expertbasedmedicationreviewstoreducepolypharmacyinolderpatientsinprimarycareanorthernitalianclusterrandomisedcontrolledtrial
AT piccoliorigiuliano expertbasedmedicationreviewstoreducepolypharmacyinolderpatientsinprimarycareanorthernitalianclusterrandomisedcontrolledtrial